Myasthenia Gravis Serum

About Myasthenia Gravis Serum

Human Myasthenia Gravis Serum for Autoimmune Neuromuscular Research

Our Myasthenia Gravis Serum is sourced from IRB-consented donors clinically diagnosed with myasthenia gravis (MG). Each sample is processed and frozen within 24 hours of collection to keep the pathogenic autoantibody and the surrounding soluble proteome intact and consistent from lot to lot. Serum is acellular and is the definitive matrix for MG serology, since the disease is diagnosed and subtyped almost entirely on circulating autoantibody specificity.

Why MG Serum for Autoimmune Neuromuscular Research

Myasthenia gravis is a prototypical antibody-mediated autoimmune disease of the neuromuscular junction. Autoantibodies against postsynaptic components of the junction impair neuromuscular transmission, producing the fatigable weakness that defines the condition. Because the effector molecule is a circulating immunoglobulin, serum is not merely convenient here — it is the specimen in which the pathogenic agent itself resides.

• Acetylcholine receptor autoantibodies — the most common autoantibody in generalised MG; they cause receptor crosslinking and internalisation, complement-mediated damage to the postsynaptic membrane, and direct blockade of acetylcholine binding.
• MuSK autoantibodies — predominantly IgG4, these disrupt agrin-LRP4-MuSK signalling required to cluster acetylcholine receptors, and define a clinically distinct subtype.
• LRP4 and clustered-AChR reactivity — relevant to donors negative on conventional assays, and central to next-generation cell-based serology development.
• Complement activation — AChR-antibody-mediated disease proceeds in part through the classical complement pathway to membrane attack complex formation, which is the rationale for complement-inhibitor therapeutics and their pharmacodynamic markers.
• IgG subclass and Fc biology — subclass distribution differs between AChR (complement-fixing IgG1/IgG3) and MuSK (IgG4) disease, and total IgG dynamics underpin FcRn-antagonist programmes.
• Serum-specific advantage — because the pathogenic autoantibody is soluble, serum supports both diagnostic assay development and functional in vitro work such as patient-IgG transfer into cell-based systems.

Donor Stratification Available

• Autoantibody status — AChR-antibody-positive, MuSK-antibody-positive, and seronegative (double-negative) donors
• Clinical distribution — ocular versus generalised myasthenia gravis
• Thymic pathology — thymoma-associated disease, thymic hyperplasia, and post-thymectomy donors subject to documentation
• Disease activity — stable or minimal-manifestation status versus active exacerbation at the time of draw
• Treatment status — treatment-naive, acetylcholinesterase inhibitor, corticosteroid, conventional immunosuppressant, complement inhibitor, or FcRn antagonist-treated donors
• Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity

Product Features

• Collected from clinically confirmed MG donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Standard and custom aliquot volumes; volumes reported per lot

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Autoantibody status and clinical subtype reported per lot where captured
• Additional MG-specific clinical fields available on request

Applications

• AChR, MuSK and LRP4 autoantibody assay development and validation
• Cell-based and clustered-AChR serology development for seronegative donors
• IgG subclass characterisation across MG serological subtypes
• Complement activation and membrane attack complex readout development
• Pharmacodynamic assay development for complement inhibitors and FcRn antagonists
• Patient-IgG functional transfer studies into neuromuscular junction model systems
• Serum cytokine, chemokine and proteomic profiling in antibody-mediated autoimmunity
• Diagnostic reference, calibrator and control material sourcing

Other Myasthenia Gravis Specimen Types

• Myasthenia Gravis Plasma
• Myasthenia Gravis Bulk Plasma
• Myasthenia Gravis PBMC
• Myasthenia Gravis Whole Blood
• Myasthenia Gravis Leukopak
• AChR+ Myasthenia Gravis Serum
• Seronegative Myasthenia Gravis Serum

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Myasthenia gravis serum is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human serum page.